You are here: Industry Insights > Janssen

News List

Janssen gets expanded EC nod for blood cancer combo drug Imbruvica plus rituximab pharmaceutical-business-review
September 23, 2020
Janssen Pharmaceutical, part of Johnson & Johnson, has secured approval from the European Commission (EC) for expanded use of Imbruvica (ibrutinib) in combination with rituximab for previously untreated adult patients with chronic lymphocytic leukaemia.
SpringWorks, Janssen to Evaluate Nirogacestat with Teclistamab for Multiple Myeloma americanpharmaceuticalreview
September 21, 2020
SpringWorks Therapeutics has entered into a clinical collaboration and supply agreement with Janssen Biotech to evaluate SpringWorks’ investigational gamma secretase inhibitor (GSI), nirogacestat, in combination with Janssen’s bispecific antibody ...
Janssen Submits Light Chain Amyloidosis Treatment to FDA americanpharmaceuticalreview
September 17, 2020
Halozyme Therapeutics announced its collaborator Janssen Biotech has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) ...
SpringWorks Therapeutics in pact with Janssen to assess Nirogacestat with Teclistamab in patients with relapsed or refractory multiple myeloma expresspharma
September 15, 2020
Third collaboration to evaluate nirogacestat in combination with BCMA therapies across modalities.
Janssen gets EC approval for expanded use of IMBRUVICA (ibrutinib) plus rituximab to treat CLL expresspharma
September 08, 2020
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Commission (EC) has approved a variation to the marketing authorisation for IMBRUVICA (ibrutinib) ...
Janssen's lead coronavirus vaccine shows preclinical promise pharmatimes
September 07, 2020
Janssen’s lead SARS-CoV-2 investigational vaccine candidate, Ad26.COV2.S, prevented severe clinical disease in Syrian golden hamsters when challenged with SARS-CoV-2, the virus that causes COVID-19 in people.
Janssen disappointed with second NICE no for Spravato pharmatimes
September 04, 2020
Janssen says it is disappointed with second draft guidance from the National Institute for Health and Care Excellence (NICE) rejecting NHS funds for its nasal depression spray Spravato (esketamine).
Janssen to Discontinue Pimodivir Influenza Development Program americanpharmaceuticalreview
September 04, 2020
The Janssen Pharmaceutical Companies of Johnson & Johnson has made a strategic decision to discontinue the development of pimodivir, an investigational antiviral treatment for influenza A infection.
J&J’s Covid-19 vaccine prevents severe disease in preclinical tests pharmaceutical-technology
September 04, 2020
Johnson & Johnson (J&J) has reported that a Covid-19 vaccine candidate, developed by the company’s subsidiary Janssen, prevented severe disease in preclinical studies.
Canadian government strikes deals with Janssen and Novavax for COVID-19 vaccines europeanpharmaceuticalreview
September 03, 2020
The Canadian government has agreed that Janssen will supply the country with 38 million doses of its COVID-19 vaccine, while Novavax has agreed to supply 76 million doses if its vaccine.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page